@article{38cdc9e5776a4c6194642245d19a991f,
title = "Perspectives in oncology drug pricing - Reply",
author = "Goldstein, {Daniel A.} and Howard, {David H.} and Flowers, {Christopher R.}",
note = "Funding Information: Dr Howard has received research grant support from Pfizer. Dr Flowers has received institutional support from the National Institutes of Health, Abbvie, Acerta, Celgene, Gilead Sciences, Infinity Pharmaceuticals, Janssen Pharmaceutical, Millennium/Takeda, Spectrum, Onyx Pharmaceuticals, and Pharmacyclics. He is a consultant to Spectrum, Celgene, Optum Rx, Seattle Genetics, Genentech/Biogen-Idec/Roche (unpaid), and Millennium/Takeda (unpaid). He has been paid to develop educational presentations for Clinical Care Options and Educational Concepts. No other disclosures are reported.",
year = "2016",
month = mar,
day = "1",
doi = "10.1001/jamaoncol.2015.4997",
language = "אנגלית",
volume = "2",
pages = "402",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "3",
}
